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Abstract VIP17 is a proteolipid enriched in the CHAPS-insolu-
ble complexes from MDCK cells, and a candidate component of 
the molecular machinery responsible for the sorting and targeting 
of proteins to the apical surface. Cloning and sequencing of the 
cDNA encoding the protein revealed that it is the canine homolog 
of the human and rat MAL proteins. Analysis by immunofluores-
cence microscopy of epitope-tagged VIP17/MAL expressed tran-
siently in BHK cells and stably in MDCK cells revealed a perinu-
clear, vesicular, and plasmalemmal staining. In MDCK cells the 
distribution was mainly in vesicular structures in the apical cyto-
plasm. These and other results suggest that VIP17/MAL is an 
important component in vesicular trafficking cycling between the 
Golgi complex and the apical plasma membrane. 
Key lvords: Madin-Darby canine kidney cell; Proteolipid; 
Apical transport; Myelin biogenesis; Detergent-insoluble 
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1. Introduction 
Epithelial cells generate and maintain a polarized cell archi-
tecture to perform vectorial functions in secretion, absorption, 
and ion transport. The epithelial plasma membrane is segre-
gated into apical and basolateral domains which diffel' in pro-
tein and lipid composition [\,2]. In Madin-Darby canine kidney 
(MDCK) cells biosynthetic sorting takes place in the trans 
Golgi network (TGN) [3,4]. Here apical and basolateral trans-
port vesicles are formed to deliver their cargo to the respective 
membrane domains [5]. To identify putativc sorting and target-
ing machinery, we have immunoisolated the transport vesicles 
and analyzed their protein composition in 2D gel electrophore-
sis [6]. Several of these proteins were found to form a detergent-
insoluble complex with an apical marker protein, the influenza 
virus hemagglutinin [7,8]. Among these, the first to be charac-
terized was VIP21/caveolin, a protein also localizing in the 
Golgi complex and in plasmalemmal caveolae [7-11]. A second 
component, named VIP36, was a new type I transmembrane 
protein with a N-terminal domain showing homology to legu-
minous plant Iectins [12]. 
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Here in this paper we have identified and characterized a 
third protein, which was referred to as C14 in the 2D gel 
analysis of apical and basolateral vesicles [6-8]. According to 
our nomenclature we have named the protein VIP17 [13]. 
Analysis of the cDNA encoding VIP17 demonstrated that it 
is the canine homolog of human and rat MAL, a protein previ-
ously described with unknown function, which is expressed in 
T cells, SchWal1l1 cells, oligodendrocytes, and also in the kidney 
[14-16]. 
2. Materials and methods 
2.1. Materials 
Monoclonal anti-HA epitope 12CA5 was from Boehringer, Ger-
many; polyc\onal anti-caveolin (N-20) from Santa Cruz Biotechnology, 
Santa Cruz, CA, USA; donkey anti-mouse and anti-rabbit IgG 
(Rhodamine-conjugated) from Dianova, Hamburg, Germany; pBK-
CMV plasmid from Stratagene, CA, USA; 3-[(3-cholamidopropyl)di-
methylammonio)-l-propane sulfonate (CHAPS) and the Silver Stain kit 
from Sigma, MO, USA. 
Polymerase chain reaction (PCR) on eDNA was performed using 
Dynazyme DNA polymerase from Finnzymes Oy, Espoo, Finland. 
Oligonucleotides and PCR primers were prepared by the oligonucleo-
tide synthesis facility, and seq\lenCe reactions on both strands of DNA 
by the DNA sequence facility, both at the EMBL, Heidelberg, Ger-
many. 
2.2. Cell culture 
MDCK strain II and BHK21 cells were grown and passaged as 
previously described [6,7]. 
2.3. eDNA cloning and sequence analysis 
CHAPS pellets from dog kidney and 2D gel electrophoresis were 
carried out according to Fiedler et al. [8). The spots corresponding to 
C14 (6-8] were excised from Coomassie blue stained gels. Amino acid 
sequence analysis on tryptic fragments was performed as described [7). 
Two sequences were obtained KQYHENISAVVF and PAAASGGS-
SLPSGF. These were used to screen the Swissprot database with 
MPseareh [17) (accessible bye-mail under Blitz@EMBL-Hei-
delberg.de) and to prepare the degenerated oligonucleotides for PCR 
amplification of cDNA from MDCK cells. Cytoplasmic RNA was 
isolated from MDCK cells as described [18), and converted into cDNA 
by priming with oligo-dT and reverse transcriptase. The degenerated 
primers 5'-G(TC)(TA)(GC)ICTICC(ACGT)AG(TC)GGITT-3' (sense) 
and 5'-IAT(AG)TT(CT)TC(AG)TG(AG)TA(CT)TG(CT)TT-3' (an-
tisense) were synthesized and used to amplify the cDNA by PCR [12]. 
Based on the sequence obtained from the PCR fragment, new oligonu-
cleotides directed either upstream or downstream on the cDNA were 
synthesized. The downstream primer was used in combination with a 
oligo-dT primer to obtam the 3'-end sequence of the VIP)7 cDNA as 
described [19). The 5'-end of the VIP17 eDNA was obtained by using 
the upstream primer in an anchor ligation based PCR [20). Finally we 
amplified a cDNA fragment corresponding to the coding region of the 
VIP17/MAL cDNA and cloned it into pBAT-4 (BaI11HI-blunted, 
Ncol), which is a T7-based Escherichia coli expression vector (Peranen, 
unpublished). DNA sequencing was performed on both strands on 
cDNAs obtained frol11 separate peR, using the dideoxynucleotide 
chain termination method [21]. 
Sequence analysis was carried out with the Wisconsin University 
GCG software package (Madison, WI, USA) [22]. EMBLlGenbank 
and Swissprot databases were searched for homology to VIPl7. 
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2.4. E.,traction and {'urijl< almn I~(proteo/ipitl.~ 
MDCK (;ell~ (about HlJ% cont1uent) were scraped in ice-cold phos-
phate butTer (NaCI 135 mM, KC12.7 mM, Na2HP04 6.5 mM, KH1P04 
1.5 mM) with a rubber policeman from 4 x 530 em' dishes, washed 
with ice-cold SHE buffer (sucrose 250 mM, HEPES/NaOH 10 mM, 
EGTA 2 mM, pH 7.4) and resuspended in the same buffer with a 
cocktail of protease inhibitors (chymostatin, Ieupeptin, antipain, pep-
statin, 10 ,ugfml each). Cells were disrupted by sonication (Branson tip 
sonicator; 30 s, 0.5 Hz, strength 3) and centrifuged for 30 s at 10,000 x g. 
The pellet was washed once and the supernatants pooled (PNS, 3 mI, 
10 mg/ml). 
For chloroform/methanol extraction the PNS was stirred 50 min at 
4°C with 15 volumes of chloroform/methanol 2 : I and filtrated through 
a Whatman fllter paper. Then 0.2 volumes of water were added and 
mixed 30 min at 4°C, After phase separation at 4°C for 3 hours, the 
water phase was removed and the organic phase dried under a stream 
of nitrogen. 
The Iioated membrane fraction was prepared according to Fiedler et 
al. [8] from 12 x 150 cm2 dishes by flotation of the PNS brought to 2 M 
sucrose and overlayed with 7.5 ml of 1.2 M and 3 ml 0[0.8 M sucrose 
in 10 mM HEPESlNuOH (pH 7.4) and 2 mM EGTA, and centrifuged 
at 4°C for 20 h at 38,000 rpm in a SW40 rotor (Beckman, CA, USA). 
The membrane fraction was recovered from the 0.8/1.2 M sucrose 
interface (20 ml, 0.5 mg/ml). The CHAPS pellet, prepared according to 
Fiedler et a1. [8] was solubilized in 0.1% SDS, 0.192 M glycine, 25 mM 
Tris pH 8.3, and extracted into chloroform-methanol. The extracted 
material from the PNS or the CHAPS pellet was dissolved in 500 J.11 of 
chloroform/methanollacetic acid/HCI(lO mM) 2: I :0.03 :0.03 and 
loaded onto a 65 em x 1 cm LH-20 column (Pharmacia) and eluted 
with the same eluent at 800 ,ullmin (600 ,ullfraction). For SDS-PAGE 
1/20th and 116th of the PNS and CHAPS pellet extracts were loaded, 
while 1I5th and l/3rd, respectively for 2D gel electrophoresis. 
2.5. SDS-PAGE and 2D gel electrophoresis 
SDS-PAGE on 15% gels and resolution of proteins in two dimensions 
by isoelectric focusing and SDS-PAGE (15% gels) was performed as 
described [5,6,23]. The proteolipid fractions, dried under nitrogen 
stream, were resuspended by vortexing directly into sample buffer [241 
or 2D gel sample buffer. Detection of proteins was by silver stain. 
2.6. Epifope tagging and transfection 
A construct encoding VIP17/MAL with the hemagglutinin (HA) 
l2CA5 epitope [25,26] at the N terminus was created by PCR (overlap 
extension) using pBAT-VIPI7 as a template. A 63 bp oligonucleotide 
encoding a Ncol restriction site at the 5'-end and the amino acids 
MOYPYDVPDYASGMAPAAA (epitope in bold), and a 3' specific 
CCCAAGCTTTATGAAGACTTCCATCTG oligonucleotide were 
used according to Ho et al. [27]. The amplification product (Neol, 
BamHI-blunted) was then cloned into pBAT4 (Ncol, HindIIr-blunted) 
creatingpBAT-Y17HA. Expression of the tagged protein in BHK cells 
with the T7 RNA polymerase-recombinant vaccinia virus [28] was 
performed as described [7,29]. Stable MDCK cell clones expressing the 
tagged protein were created by electrotransfection of cells (according 
to [30]) with a plasmid (pC MY-Y 17HA) created by inserting the frag-
ment coding for the tagged protein cut out from pBAT-VI7HA (Not!, 
Neal-blunted), into the pBK-CMY vector (NOlI, NheI-bJunted). 
2.7. Conventional and confacld immunofluorescence 
Immunofluorescence was performed according to Fiedler et al. [31] 
omitting the denaturation step with guanidine. 
3. Results 
3.1. cDNA cloning and sequence analysis 
VIPl7 protein was purified from Coomassie blue stained 20 
gels of the CHAPS pellet from total membrane fraction of dog 
kidney according to Fiedler et aL [8J and, after trypsin diges-
tion, the fragments were subjected to amino acid sequence 
analysis. The complete nucleotide sequence was obtained as 
described in section 2. 
An EMBVGenBank database search (FASTA program, 
GCG software package) revealed homology with the MAL 
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Fig. I. Alignment of canine YIPI7{MAL with the human (hMAL) and 
rat (rMAL) MAL proteins. Dots represent identity, capital letters the 
consensus according to the Pretty program of the GCG software pack-
age. Accession numbers: VIP17IMAL, X92505; MAL. M15800; rMAL, 
X82557; MYPI7, U31367. 
protein described in T-lymphocytes [14, 32J and the rMALI 
MVPl7 protein found in rat myelin [15,16]. Fig. 1 shows the 
alignment of the three proteins, with identical aminoacid resi-
dues represented by dots and the consensus (Pretty program, 
GCG software package) in capital letters. The 88% and 87% 
identity with the MAL and rMAL proteins respectively sug-
gests VIPl7 to be the canine homolog of the MAL protein. We 
call the protein YIP17/MAL. 
3.2. VIP 171 MAL is a proteolipid 
The proteolipid fraction from MOCK cell post-nuclear su-
pernatant was isolated by a standard chloroform/methanol ex-
traction procedure for lipids. The extracted material was delip-
idated by LH-20 gel filtration [33]. Three peaks were obtained 
(Fig. 2a). The first peak contained proteolipids. Phospholipids 
were found in the second peak, whereas cholesterol (as well as 
other small lipidic molecules) was in the third peak (analysis by 
thin layer chromatography, data not shown). An SDS-PAGE 
analysis (Fig. 2b, lane 1) of the first peak fraction revealed the 
presence of several proteins. The prominent band around 17 
kOa was identified as YIPI7/MAL according to the 2D gel 
analysis showed in Fig. 2c. The isoelectric point and the appar-
ent molecular weight were identical to those ofVIPl7 in immu-
noisolated TGN-derived vesicles [6-8J. This is in agreement 
with studies demonstrating that the MAL protein from T-Iym-
phocytes also is soluble in chlorofonnlmethanol [32J. 
A proteolipid fraction from the CHAPS pellet was also pre-
pared. The chloroform/methanol extracted material contained 
little lipid. The LH-20 column elution profile almost totally 
lacked the second and third peaks, and the low content oflipids 
was confirmed by thin layer chromatographic analysis which 
showed the expected enrichment in sphingolipids and cholest-
erol (data not shown and see Fiedler et aL [8]). Lane 2 in Fig. 
2b and Fig. 2d show the SDS-PAGE and 2D gel patterns of 
proteolipids present in the CHAPS pellet. Only VIP17/MAL 
and another unidentified proteolipid were detected. 
3.3. Cellular locali=ation of VIP17l1vfAL ill BHK and MDCK 
cells 
VIPI7/MAL carrying the HA epitope recognized by the 
12CA5 monoclonal antibody was transiently expressed in BHK 
cells using the T7 RNA polymerase recombinant vaccinia virus 
expression system [7,28,29J. After 2.5 hours of expression the 
tagged V[PI7/MAL protein was localized to the perinuclear 
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Fig. 2. Proteolipid purification from the PNS and the CHAPS pellet. (A) Elution profile (measured by optical density at 280 nm) of the chloroform! 
methanol extract from the PNS, chromatographed on the LH-20 column. (B) SOS-PAGE comparison of the proteolipid pattern from the PNS (lane 
1) and the CHAPS pellet (lane 2). (CD) 2D gel analysis of the proteoliplds extracted from the PNS (C) or the CHAPS pellet (d). Basic side is on 
the right. The same molecular weight markers (horizontal bars) are used as in (B). 
area and to punctate structures throughout the cell (Fig. 3a). 
After a chase with cycloheximide (4 hours of expression fol-
lowed by 90 min cycloheximide treatment) the perinuclear 
staining decreased and surface staining was seen, whereas the 
punctate-vesicular pattern was unchanged (Fig. 3b). No signal 
was detected from non permeabilized cells suggesting that the 
N terminus is on the cytoplasmic side (not shown). 
The tagged protein was also stably expressed in MDCK cells. 
No difference in the gross morphology could be observed be-
tween the expressing clone and the parental line. The VIPl71 
MAL expressing MDCK cells exhibited nonnal transepithelial 
resistance and the distribution of the apical marker 114 kDa 
protein and the basolatcral marker 58 kDa protein was polar-
ized in the filter-grown cells (not shown) [34]. 1I11muno!1uores-
cence analysis of the tagged protein in the confocal microscope 
revealed a punctate-vesicular and plasmalemmal pattern in 
agreement with the results obtained in BHK cells. In addition, 
a preferential localization towards the apical side could be 
observed in the comparison with the VIP211caveolin staining 
(Fig. 4). 
4. Discussion 
VIP211caveolin, VIP36 and VIPl7fMAL were all identified 
as components of a detergent-insoluble complex. which forms 
when the newly synthesized influenza virus hemagglutinin 
reaches the TGN in MDCK cells [7]. This high molecular 
weight complex is then incorporated into vesicles routed to the 
apical membranc. The discovery that these same proteins could 
be isolated by an extremcly simple procedure relying on their 
468 
Fig. 3. Localization of tagged VIP17/MAL in transfected BHK cells 
grown on coverslips after 2.5 hours of expression CA), or 4 hours of 
expression followed by 90 min chase with cycloheximide (B). Monoclo-
nal allti-HA (l2CA5 epitope) was used at a concentration of I ,Llg/m!. 
CHAPS-insolubility at 4°C, enabled us to characterize these 
major proteins of the CHAPS complex [7,8,12]. Because deter-
gent-insolubility is such a non-specific purification criterion, it 
is reassuring that all of these three proteins are indeed localized 
in the post-Golgi trafficking routes to the cell surface. The 
intracellular localization ofVIP17/MAL was analyzed express-
ing the epitope-tagged protein both in BHK cells and MDCK 
cens. The analysis showed a very similar cellular distribution 
to that previously reported for VIP36 [12]. The VIP17/MAL 
protein is seen in a perinuclear location probably correspond-
ing to the Golgi complex, in cytoplasmic vesicles, and on the 
cell surface. During treatment with cycloheximide to block pro-
tein synthesis, the perinuclear labelling of VrPI7/MAL de-
creased in BHK cells, presumably because its steady-state local-
D. Zacchetti et (II. / FEES Letters 377 ( 1995) 465-469 
ization is more towards post-Golgi compartments, as was seen 
in stably transfected MDCK cells. 
VIP211caveolin, VIP36 and VIPl7/MAL are not only present 
in apical vesicles, but are also in basolateral vesicles [6]. The 
reason for this is not yet clear, but we favor the possibility that 
these proteins also playa role in basolateral to apical transcy-
tosis. VIP211caveoIin is also known to form caveolae on the 
basolateral surface [9]. 
Cloning and sequencing the cDNA encoding VIPl7 revealed 
that it is the canine homolog of the human MAL protein which 
is expressed in the late stages of T-cells maturation [14,32]. 
Recently a rat myelin protein has also been shown to be a 
homolog of MAL and VIPI7 [15,16]. MAL belongs to the 
group of proteins called proteolipids [35,36] based on their 
solubility in organic solvents and on their high content of hy-
drophobic amino acids [32]. We showed here that VIPI7/MAL 
can be also purified by chloroform/methanol extraction. 
VIPl7/MAL is expressed in white and grey matter oligoden-
drocytes, in myelinating Schwann cells and in the kidney. 
Amazingly, rat MAL is not expressed in the thymus [15,16]. 
Thus, the VIP17/MAL has a very specific tissue expression. 
Although its function in myelin is not known, it is important 
to point out that VIPI7/MAL is expressed at the time when 
myelin sheets are being formed [15]. Kim et al. demonstrated 
that VIP17/MAL is a major component of CHAPS-insoluble 
complexes in oligodendrocytes starting to produce myelin. 
VIP211caveolin and VIP36 were not identified in these com-
plexes [16]. Since myelin is enriched in glycolipids, particularly 
galactosylceramide and sulfatide [37], it is tempting to speculate 
that VIP 17/MAL has a function in glycolipid transport to the 
cell surface, i.e. to the myelin sheets in oligodendrocytes and 
Schwann cells and to the apical surface in kidney cells. This 
conforms with our working hypothesis for apical membrane 
biogenesis, involving glycolipid-cholesterol rafts as sorting 
platform that load cargo in the TON destined to the apical 
membrane [13]. Recent results in our laboratory suggest that 
the apical traffic route lIses a mechanism for docking and fusion 
different from that employing the RabINSF/SNAP/SNARE 
machinery [38]. We, therefore, expect to unravel a new mode 
of vesicular transport depending on known and unknown VIPs 
and annexins [31]. Glycolipid rafting may indeed be involved 
not only in apical and myelin biogenesis, but also in the trans-
port of newly synthesized proteins to the axolemma in neurons 
[39], as well as in endocytosis and transcytosis involving surface 
caveolae [40]. Only further work will demonstrate whether this 
hypothesis is correct or not. 
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